ライフサイエンスコーパス: maximum dose

1 nd a 20-wk open-label extension (OLE) at the maximum dose.

2 ich however was applied at a 50 times higher maximum dose.

3 r soy, and most reactions occurred after the maximum dose.

4 placebo or flexibly dosed pramipexole (mean maximum dose=1.7 mg/day, SD=1.3) added to existing mood

5 eceive intravenous dexamethasone (0.5 mg/kg, maximum dose 10 mg) or saline, every 6 hrs for six doses

6 l of placebo (bid), low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid), and moderate-dose MPH (0.6 mg/

7 aily subcutaneous doses of 1 mg/kg anakinra (maximum dose, 100 mg) or saline (placebo).

8 rubicin 50 mg/m(2), vincristine 1.4 mg/m(2) (maximum dose 2 mg), and rituximab 375 mg/m(2) on day 1,

9 andomized to MTX 15 mg/m2 body surface area (maximum dose 20 mg) once a week while continuing on UDCA

10 m and droperidol as directed by radiologist, maximum doses 20 mg and 5 mg respectively).

11 0 mg bid), and moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid).

12 ioperative dose of dexamethasone (0.5 mg/kg; maximum dose, 20 mg), with an equivalent volume of 0.9%

13 citalopram was 16.5 (6.5) mg by mouth daily (maximum dose, 20 mg/d).

14 umine [0.1 mmol per kilogram of body weight, maximum dose, 20 mL]) for hepatobiliary indications were

15 and >/= 25 kg) and chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years) was we

16 months of daily self-administered isoniazid (maximum dose, 300 mg; 9H-SAT).

17 mumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for

18 ptomatic myeloma were also treated as above (maximum dose 400 mg) and received dexamethasone 20 mg/m(

19 usion of IdU (200 mg/m(2) body surface area; maximum dose, 400 mg) over a 30-minute period; the IdU h

20 rsus 4.7 mg/day), a longer number of days to maximum dose (5.7 days versus 3.9 days), and a maximum r

21 continue on risperidone if they had a higher maximum dose (5.7 mg/day versus 4.7 mg/day), a longer nu

22 /kg/week), etanercept alone (0.8 mg/kg/week, maximum dose 50 mg), or etanercept plus MTX for 3 years

23 domization to degludec/liraglutide (n = 278; maximum dose, 50 U of degludec/1.8 mg of liraglutide) or

24 , to receive 25% albumin (2 g [8 mL] per kg; maximum dose 750 mL) or the equivalent volume of isotoni

25 zophrenia was shown in early phase 2 trials (maximum dose, 750 mg/d).

26 tidepressant regimens, received either DHEA (maximum dose = 90 mg/day) or placebo for 6 weeks in a do

27 flexibly dosed treatment with oxcarbazepine (maximum dose 900-2400 mg/day) or placebo.

28 ntine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP-DOT) and 31% for 9 months of

29 f directly observed once-weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900

30 atment-refractory depression (at least three maximum-dose, adequate-duration medication treatments),

31 atment-refractory depression (at least three maximum-dose, adequate-duration medication treatments),

32 The maximum dose administered was 1 x 10(11) PFU per dose.

33 rsensing was observed in 20 of 21 devices at maximum doses and in 17 of 20 devices at typical doses.

34 nstraint; IPSA2, without a constraint on the maximum dose; and IPSA2-0, identical to IPSA2 but withou

35 The maximum dose at mammography assessed in 1-mm(3) voxels w

36 s of SDI at TL were age, corticosteroid use (maximum dose at T0), number of American College of Rheum

37 to phenotypic or microenvironmental factors; maximum dose density chemotherapy hastens rapid expansio

38 At the maximum dose, diltiazem (maximum relaxation, 95%+/-2% [p

39 abdomen was 15.12 cGy and 0.97 cGy while the maximum dose for the skin was 17.3 cGy and 1.32 cGy.

40 gnant lesions in doses of 2 MBq/kgBW and the maximum dose image (gold standard).

41 and a phase II trial of HPV16 L2E7E6 at the maximum dose in 29 women with high-grade anogenital intr

42 tomography: IPSA1, with a constraint on the maximum dose in the target volume; IPSA1-0, identical to

43 The maximum dose-intensity achieved with the first two cycle

44 The maximum dose is calculated as a function of 5 variables:

45 5% of the critical structure volume (D(5%)), maximum dose, mean dose, and normal tissue complication

46 longed reduction of WBCs was observed at the maximum dose of (90)Y-anti-CD20 IgG, whereas pretargetin

47 In tumor tissue, a maximum dose of 12.2 Gy per GBq of (131)I-BA52 was calcu

48 ere then treated in the phase 2 study at the maximum dose of 130 mg/m2 per day for 3 days.

49 Escalation of oxaliplatin to the maximum dose of 130 mg/m2 was well tolerated in all pati

50 A model was developed that calculates the maximum dose of 131I that may be dispensed to an outpati

51 g, which could be increased, as needed, to a maximum dose of 150 mg daily, for a total of 12 weeks.

52 ramate doses were titrated over 6 weeks to a maximum dose of 150 mg twice daily.

53 xicity, a dose escalation of paclitaxel to a maximum dose of 170 mg/m(2)/d was prescribed.

54 eceived riociguat individually adjusted to a maximum dose of 2.5 mg three times a day.

55 eceived riociguat individually adjusted to a maximum dose of 2.5 mg three times per day.

56 t an initial dose of 50 mg/d (escalated to a maximum dose of 200 mg/d based on tolerability and respo

57 The maximum dose of 20kJ/m(2) produced 3.5-4mug vitamin D3/c

58 r day, up-titrated until intolerance or to a maximum dose of 25 mg/kg or 50 mg/kg per day (dependent

59 omipramine administered for 12 weeks, with a maximum dose of 250 mg/day.

60 tching placebo dose adjusted from 50 mg to a maximum dose of 300 mg.

61 (2)/d with intrapatient dose escalation to a maximum dose of 300 mg/m(2)/d.

62 y was performed using three-min stages and a maximum dose of 40 microg/kg per min.

63 was started at 200 mg/d, and escalated to a maximum dose of 400 mg/d.

64 reated patients), administered at an average maximum dose of 49 mg/day.

65 ightmare response over 6 weeks to a possible maximum dose of 5 mg midmorning and 20 mg at bedtime for

66 doses given on the first day, including the maximum dose of 500 mg peanut flour (cumulative dose, 99

67 2)/d, with intrapatient dose escalation to a maximum dose of 500 mg/m(2)/d.

68 ting dose was 2 microg/kg/d and increased to maximum dose of 6 microg/kg/d (average dose, 0.33 mg/d).

69 MAS-ER doses were titrated over 2 weeks to a maximum dose of 60 mg daily, and topiramate doses were t

70 A dose escalation to a maximum dose of 60 mg/m2/d was prescribed.

71 ose of 150 mg per day that was adjusted to a maximum dose of 600 mg per day or matching placebo for u

72 as increased by 200 mg every 2 weeks until a maximum dose of 800 mg or prohibitive toxicity was reach

73 A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was r

74 upper GI tract, which was dose-limiting at a maximum dose of 875 mg/m(2) (doxorubicin equivalent, 25

75 The mean (SD) maximum dose of citalopram was 16.5 (6.5) mg by mouth da

76 iology and Chronic Health Evaluation II, and maximum dose of norepinephrine day 1) (hazard ratio, 2.9

77 The FABF response to the maximum dose of norepinephrine was also attenuated durin

78 h symptoms that were not controlled with the maximum dose of opioid were treated with adjunctive phen

79 The maximum dose of sertraline was 50 mg/day.

80 hours), inotrope score (calculated from the maximum dose of the individual inotropic agents administ

81 The maximum dose of topotecan plus M6620 is tolerable.

82 We found that the maximum dose of UV radiation in the B range (UVB; 280-32

83 Maximum doses of either carbachol or isoprenaline had no

84 When residual inflammation remains after maximum doses of single agents, as is usually the case,

85 with hypertension (using >/=2 medications at maximum doses or >2 at moderate doses) and a body mass i

86 ied by dose of pirfenidone (2403 mg/day [the maximum dose] or <2403 mg/day).

87 The maximum number of treatments and maximum dose per treatment are set by fungicide manufact

88 The maximum dose received for the abdomen was 15.12 cGy and

89 The maximum dose that could be administered daily was limite

90 followed by an extension phase involving the maximum dose that could be administered without adverse

91 increasing the dose of dBG to 300 mg/m2 (the maximum dose that could be delivered i.p. in a standard

92 At the maximum doses that were associated with an acceptable le

93 Maximum dose to the vessel wall was 30 to 55 Gy.

94 gs challenge the existing flawed paradigm of maximum dose treatment, a strategy that inevitably produ

95 Maximum dose was 28 mg per day, titrated against bodywei

96 predefined stabilization criteria after the maximum dose were classified as treatment failure, at wh

97 th charged particles can potentially deliver maximum doses while minimizing irradiation of surroundin

98 The MTD was defined as the maximum dose with </= 20% risk of severe toxicity.

99 mg of liraglutide) or glargine (n = 279; no maximum dose), with twice-weekly titration to a glucose